Pliant Therapeutics is committed to the discovery and development of new therapies for fibrotic diseases, an area with high unmet medical need. Our scientific rationale for utilizing the UKB data is to analyze biomarker, genetic, and other health related data to enable the evaluation of molecular drivers, novel therapeutic targets, and biomarkers for fibrotic lung disease using a population-scale resource that is only available through the UKB. We aim to (1) identify novel genetic and biomarker associations among related respiratory disorders based on UKB patient data, (2) understand how genetic factors relate to disease progression and outcomes and (3) investigate how proteomic biomarkers may be utilized to identify patient populations that are most likely to benefit from new therapies. We anticipate these findings will support more effective drug discovery and development for fibrotic lung disease and related fibrotic disorders.
